PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot… - Molecular cancer, 2023 - Springer
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …

Gastrointestinal stromal tumours

JY Blay, YK Kang, T Nishida… - Nature reviews Disease …, 2021 - nature.com
Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …

[HTML][HTML] Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer

MB Buechler, W Fu, SJ Turley - Immunity, 2021 - cell.com
Fibroblasts and macrophages are present in all tissues, and mounting evidence supports
that these cells engage in direct communication to influence the overall tissue …

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

MC Heinrich, RL Jones, M von Mehren… - The Lancet …, 2020 - thelancet.com
Background Targeting of KIT and PDGFRA with imatinib revolutionised treatment in
gastrointestinal stromal tumour; however, PDGFRA Asp842Val (D842V)-mutated …

Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update

R Roskoski Jr - Pharmacological research, 2021 - Elsevier
Owing to the dysregulation of protein kinase activity in many diseases including cancer, the
protein kinase enzyme family has become one of the most important drug targets in the 21st …

Therapeutic advances of targeting receptor tyrosine kinases in cancer

C Tomuleasa, AB Tigu, R Munteanu… - … and Targeted Therapy, 2024 - nature.com
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …

[HTML][HTML] Current clinical management of gastrointestinal stromal tumor

K Akahoshi, M Oya, T Koga… - World journal of …, 2018 - ncbi.nlm.nih.gov
Gastrointestinal stromal tumors (GISTs) are the most common malignant subepithelial
lesions (SELs) of the gastrointestinal tract. They originate from the interstitial cells of Cajal …

[HTML][HTML] Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies

K Søreide, OM Sandvik, JA Søreide, V Giljaca… - Cancer …, 2016 - Elsevier
Abstract Background Gastrointestinal stromal tumours (GISTs) are rare, yet the most
common mesenchymal tumour within the digestive tract. Lack of diagnostic criteria and no …

International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

L Amar, K Pacak, O Steichen, SA Akker… - Nature Reviews …, 2021 - nature.com
Approximately 20% of patients diagnosed with a phaeochromocytoma or paraganglioma
carry a germline mutation in one of the succinate dehydrogenase (SDHx) genes (SDHA …

New treatment strategies for advanced-stage gastrointestinal stromal tumours

LR Klug, HM Khosroyani, JD Kent… - Nature reviews Clinical …, 2022 - nature.com
When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …